Overcome 340B ESP & Other Manufacturer Restrictions With Software And Human Insight

August 28, 2024340B, 340B ESP, Bedside Prescription Delivery, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Overview, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More

Using 340B To Optimize Patient Care And ROI Throughout Your Health System

August 7, 2024340B, 340B ESP, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, Prescription Discounts, Readmissions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of ProxsysRx’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More

Empower Your Health System’s 340B Program With Analytics

July 10, 2024340B, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Medication Compliance, Patient Eligibility, TPA / TPAs

The automated approach to optimizing 340B savings & patient care while overcoming manufacturer restrictions NOTE: The purpose of this article is to highlight features and functionality any 340B platform needs to optimize a health system’s 340B savings and revenue. That said, we determined that the easiest way to report those features was to describe the … Read More

The Best 340B Program Is More Than Just A 340B Program. Much More.

March 12, 2024340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

Congress established the 340B program in 1992 to help non-profit hospitals fill-in the significant revenue gaps inherent to their business models. What the bill’s supporters did not foresee, and what very few eligible health systems realize — even today — is that 340B can function as the central hub of a multi-point program. One that … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

February 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

The 2023 Guide To Implementing An Effective 340B Program

May 24, 2023340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, PBM, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More

Why 340B Hospitals Should Now Build Their Own Specialty Pharmacies

May 3, 2023340B, 340B ESP, Covered Entities, Drug Manufacturer Restrictions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More

Manufacturers Accelerate Pace And Severity Of 340B Drug Pricing Restrictions

May 1, 2023340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Requirements, TPA / TPAs

There’s an old saying that it’s better to be rich and guilty than poor and innocent. It’s a sad truth that accurately reflects the current state of 340B manufacturer restrictions, particularly in the wake of the January 30, 2023 decision by the U.S. Court of Appeals for the Third Circuit — which was largely in … Read More

Brick Walls: Dealing With 340B Manufacturer Restrictions.

February 23, 2023340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, PBM, Requirements, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

A ProxsysRx Team Member Speaks Out. I joined ProxsysRx in early 2021, and I’ve been devoted to 340B program management full-time since early 2022. I’m no stranger to heavily regulated programs. Nearly my whole professional career has been in some aspect of public health — preclinical, clinical and now post-clinical. I’m currently fully devoted to … Read More

Which TPAs Are The Best At Optimizing 340B Savings And Revenue?

December 8, 2022340B, Audit, Compliance, Contract Pharmacy, Covered Entities, TPA / TPAs

A covered entity’s guide to selecting TPAs for its 340B program TPAs play a critical role in any covered entity’s 340B program. It’s their job to match contract pharmacies’ prescription claims with patient data provided by the health systems they serve, to determine 340B eligibility — and generate entity savings. Without those matches, no prescriptions … Read More